



1 Factors beyond diabetes facilitating the development and evolution of diabetic nephropathy	1
<i>Diego F. Márquez, Luis M. Ruilope</i>	
Introduction	1
Age	3
Sex disparities	3
Ethnic disparities/genetic factors	4
Smoking status	4
Diabetic vs. non-diabetic CKD	4
Hyperglycemia	5
Lipid profile	6
Diet	6
Uric acid	7
Sleep duration	8
Hypertension	8
Arterial stiffness	9
Atrial fibrillation	9
Albuminuric and non-albuminuric CKD	10
Conclusions	11

2 Intensified multifactorial intervention in patients with kidney disease and microalbuminuria	16
<i>Clara García-Carro</i>	
Introduction	16
Classical clinical trials assessing multifactorial interventions	17
Modern clinical trials assessing multifactorial interventions	21
Conclusions	24



3	Classical blockade of renin-angiotensin-aldosterone system in diabetes and non-diabetes kidney disease	25
	<i>Gates B. Colbert, Elissa Foster, Shilpa Sannapaneni, Louis Damian, Edgar V. Lerma</i>	
	History of renin-angiotensin-aldosterone system inhibition discovery	25
	Pathophysiology of renin-angiotensin-aldosterone system	25
	Pathophysiology	26
	Angiotensin-converting enzyme inhibitor	26
	Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker	27
	Direct renin inhibition	28
	Mineralocorticoid receptor antagonists	28
	Angiotensin receptor/neprilysin inhibitor	29
	Renin-angiotensin-aldosterone system in chronic kidney disease progression	29
	Renin-angiotensin-aldosterone system in diabetes mellitus	30
	Renin-angiotensin-aldosterone system inhibitors in diabetic nephropathy	31
	Angiotensin-converting enzyme/angiotensin receptor blockers affecting non-diabetic chronic kidney disease progression	31
4	SGLT2I as a renoprotective treatment for kidney disease	36
	<i>Ander Vergara, Marina López, Sheila Bermejo, Irene Agraz, María José Soler</i>	
	Introduction	36
	Cardiovascular and renal outcome trials with SGLT2i in type 2 diabetic patients	36
	Cardiorenal protective mechanisms of SGLT2i	39
	Glucose-lowering effect	39
	Weight loss	42
	Blood pressure reduction	42
	Natriuresis and protection against fluid overload	42
	Decrease in intraglomerular pressure	43
	Albuminuria reduction	43
	Decrease in visceral adipose tissue and amelioration non-alcoholic fatty liver disease	43
	Adverse events and considerations when initiating SGLT2i	45
5	Glucagon-like peptide-1 receptor agonists for cardiorenal protection in diabetes and obesity-related kidney disease	49
	<i>Marco Montomoli, Alejandra Yugueros, Luis D'Marco</i>	
	Introduction	49
	GLP-1RA in cardiorenal protection	51
	GLP-1RA in obesity and inflammation	57

GLP1-RA in patients without diabetes	59
Future investigations	61
6 Finerenone and renoprotection in diabetic kidney disease	66
<i>Fotini Iatridi, Marieta P. Theodorakopoulou, Olga Balafa, Alberto Ortiz, Pantelis Sarafidis</i>	
Introduction	66
Aldosterone and its actions on mineralocorticoid receptors	68
Pharmacological differences between steroidal and non-steroidal MRAs	69
Studies of the non-steroidal mineralocorticoid receptor antagonist finerenone in diabetic kidney disease	71
Evidence on independent effects of SGLT2is and finerenone on kidney outcomes	75
Evidence on independent effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and finerenone on kidney outcomes	76
Mechanisms possibly involved in the renoprotective actions of finerenone	76
Conclusions	78
7 New options for treating diabetic and non-diabetic kidney disease	83
<i>Beatriz Fernández-Fernández</i>	
Introduction	83
Inflammation in diabetic kidney disease	84
Improve residual cardiorenal risk in patients with chronic kidney disease and type 2 diabetes: clinical update and unmet needs	84
Ongoing clinical trials and potential anti-inflammatory actions with new drugs targeting diabetic kidney disease	87
Endothelin receptor antagonists	87
Soluble guanylyl cyclase activators	88
Targeting cytokines	88
Targeting complement	89
Drug repositioning for chronic kidney disease, diabetic kidney disease and CVD	89
Nrf2 activators: the eternal failing star	92
What the future holds	92
Conclusions	93